Make an Inquiry
Accelerating Sleep Apnea Drug Development

Sleep apnea presents a significant therapeutic challenge, with limited pharmacological options and a high unmet clinical need. Protheragen is a specialized partner in preclinical drug development, dedicated to advancing innovative therapeutics for sleep apnea. Leveraging deep scientific expertise and state-of-the-art platforms, Protheragen delivers comprehensive preclinical solutions encompassing target validation, lead optimization, pharmacology, toxicology, and IND-enabling studies. Protheragen’s integrated approach combines rigorous scientific methodologies with advanced in vitro and in vivo models specific to sleep apnea pathophysiology. The company’s experienced team ensures each stage of development adheres to the highest standards of regulatory compliance and data integrity, facilitating a seamless transition from discovery to clinical entry. By prioritizing scientific excellence and operational efficiency, Protheragen empowers pharmaceutical partners to accelerate the development of novel sleep apnea therapies. Committed to driving therapeutic breakthroughs, Protheragen is positioned to transform promising concepts into viable clinical candidates, addressing the pressing needs of patients and the healthcare community.

What is Sleep ApneaTargets for Sleep ApneaDrug Discovery and Development ServicesWhy Choose Us

What is Sleep Apnea

Sleep apnea is a common sleep-related breathing disorder characterized by recurrent episodes of partial or complete upper airway obstruction or impaired respiratory drive during sleep. The most prevalent form, obstructive sleep apnea (OSA), results from the collapse of the pharyngeal airway due to factors such as reduced muscle tone, obesity, or anatomical abnormalities. Central sleep apnea (CSA) arises from impaired central nervous system signaling to the respiratory muscles, often linked to heart failure or neurologic conditions. Both types lead to intermittent hypoxia and sleep fragmentation, triggering sympathetic activation and contributing to cardiovascular and metabolic complications. Clinically, sleep apnea presents with symptoms such as loud snoring, witnessed apneas, nocturnal gasping or choking, and excessive daytime sleepiness. Diagnosis relies on clinical assessment and confirmation with overnight polysomnography, which quantifies the frequency of apneas and hypopneas to gauge disease severity. Home sleep apnea testing may be suitable for select patients. Management includes lifestyle modifications, positive airway pressure therapies (such as CPAP), and, in some cases, pharmacologic agents. Medications like solriamfetol, armodafinil, and modafinil can improve wakefulness in patients with persistent daytime sleepiness, while tirzepatide may be used to aid weight management. Early recognition and treatment are crucial to reduce morbidity and improve quality of life.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-2023788-19-2-tirzepatide-rec-inn-usan tirzepatide (Rec INN; USAN) 2023788-19-2 C225 H348 N48 O68 4813.451
img-178429-62-4-free-base-solriamfetol-hydrochloride-rec-innm-usan solriamfetol hydrochloride (Rec INNM; USAN) 178429-62-4 (free base) C10 H14 N2 O2 . Cl H 230.691
img-112111-43-0---modafinilr-modafinilarmodafinil-rec-inn-usanl-mo (-)-modafinil; (R)-modafinil; armodafinil (Rec INN; USAN); l-modafinil 112111-43-0 C15 H15 N O2 S 273.35
img-68693-11-8-modafinil-rec-inn modafinil (Rec INN) 68693-11-8 C15 H15 N O2 S 273.35

Learn More

Targets for Sleep Apnea

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
alpha1-Adrenoceptor (nonspecified subtype)
5-Hydroxytryptamine Receptor 2 (5-HT2) (nonspecified subtype)
Alpha-2 Adrenergic receptors (nonspecified subtype)
solute carrier family 6 member 4 SLC6A4
solute carrier family 6 member 2 SLC6A2
Sodium channel (nonspecified subtype)
purinergic receptor P2X 3 P2RX3
Orexin receptor (nonspecified subtype)
Voltage-Gated Sodium Channel Complex
T-Type Calcium Channel

Sleep apnea arises from complex disruptions in neuromodulatory pathways that regulate upper airway muscle tone, respiratory drive, and arousal thresholds. Key therapeutic targets include serotonergic (5-HT2/HTR2) and adrenergic (alpha1- and alpha2-adrenoceptors) receptors, which modulate the excitability of upper airway motor neurons and influence pharyngeal muscle activity. Cholinergic muscarinic acetylcholine receptors (CHRM) and orexin (hypocretin) receptors (HCRTR1/2) further regulate arousal and central respiratory control, impacting the body’s ability to respond to airway obstruction during sleep. Additional targets, such as the potassium calcium-activated channel (KCNMA1), control neuronal firing and muscle contractility, while monoamine transporters SLC6A2 (norepinephrine transporter) and SLC6A4 (serotonin transporter) influence synaptic neurotransmitter levels, thereby affecting upper airway tone and ventilatory stability. Therapeutic strategies are being developed to modulate these targets and restore normal respiratory function in sleep apnea. Pharmacological agents targeting serotonergic and adrenergic receptors have shown efficacy in preclinical models, with some clinical trials supporting their potential to reduce apnea frequency. Inhibitors of SLC6A2 and SLC6A4, such as selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors, are under investigation for their ability to enhance monoaminergic signaling and improve airway patency. Modulation of orexin and muscarinic pathways is also being explored to optimize arousal and respiratory drive. While several of these approaches demonstrate mechanistic promise, translation to routine clinical practice requires further validation through robust clinical trials.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates sleep apnea drug discovery by providing comprehensive screening and characterization platforms targeting key pathways such as neurotransmitter signaling, GPCR activity, and inflammation. Utilizing advanced biochemical and cell-based assays—including fluorescent, chemiluminescent, HTRF, FRET, and radioligand displacement—we evaluate potency, efficacy, and binding affinity across relevant receptors and transporters. Our robust methodologies enable detailed pharmacological profiling of candidate compounds, supporting informed lead optimization and selection. By delivering precise, actionable data on drug interactions and mechanisms, we help identify the most promising therapies for further development in sleep apnea treatment.

Glucagon Like Peptide 1 Receptor Hypocretin Receptor 1
Hypocretin Receptor 2 Muscarinic Acetylcholine Receptor (Machr) (Nonspecified Subtype)
Purinergic Receptor P2X 3 Solute Carrier Family 6 Member 2

Learn More

Why Choose Us

Choosing Protheragen for your Sleep apnea drug development needs means partnering with a team that possesses deep expertise and a proven commitment to this complex therapeutic area. At Protheragen, we specialize in Sleep apnea research and drug development, leveraging years of focused experience to deliver innovative solutions tailored to the unique challenges of this condition. Our professional teams comprise seasoned scientists and industry experts who utilize advanced technology platforms to accelerate the discovery and development process. Protheragen has established a strong track record in providing reliable, high-quality preclinical drug development services, consistently meeting project milestones and client expectations. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of development, ensuring that your programs are in safe and capable hands. Above all, Protheragen is dedicated to advancing therapeutics for Sleep apnea, striving to bring effective new treatments to patients in need. Our unwavering commitment to excellence, reliability, and scientific rigor makes Protheragen the trusted partner of choice in the field of Sleep apnea drug development.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Sleep apnea?

A: One of the primary preclinical challenges in Sleep apnea drug development is the lack of robust animal models that accurately replicate the complex pathophysiology of human Sleep apnea, including intermittent hypoxia and sleep fragmentation. Additionally, the multifactorial nature of the disease, encompassing both central and obstructive components, complicates target validation and efficacy assessment. Our company addresses these challenges by leveraging advanced in vivo and in vitro models, as well as integrating translational biomarkers to enhance the clinical relevance of preclinical studies.

Q: What are the key regulatory considerations for preclinical development of Sleep apnea drugs?

A: Regulatory agencies such as the FDA and EMA require comprehensive safety and efficacy data before approving clinical trials for Sleep apnea drugs. This includes detailed pharmacokinetic and toxicological profiles, as well as evidence of efficacy in relevant preclinical models. Special consideration must be given to endpoints that are translatable to clinical outcomes, such as reduction in apnea-hypopnea index (AHI) or improvement in oxygen saturation. Our team ensures all preclinical studies are GLP-compliant and designed to meet regulatory expectations, facilitating a smooth transition to clinical development.

Q: What technical aspects should be considered during preclinical research for Sleep apnea drug candidates?

A: Technical considerations include the selection of appropriate animal models (e.g., rodents with induced airway obstruction or genetically modified models), the use of polysomnography to monitor sleep stages and respiratory events, and the measurement of relevant biomarkers such as blood oxygen levels and inflammatory mediators. Our company utilizes state-of-the-art telemetry and respiratory monitoring systems, along with validated protocols, to generate high-quality, reproducible data that support robust preclinical evaluation.

Q: What is the typical timeline and cost for preclinical development of a new Sleep apnea drug?

A: The preclinical development phase for Sleep apnea drugs typically spans 12 to 24 months, depending on the complexity of the candidate and the required studies. Costs can range from $2 million to $6 million, encompassing pharmacology, toxicology, pharmacokinetics, and IND-enabling studies. Our company offers flexible project management and cost-effective solutions, ensuring that milestones are met on time and within budget while maintaining the highest scientific and regulatory standards.

Q: What are the key success factors in preclinical drug development for Sleep apnea?

A: Success in preclinical development for Sleep apnea drugs hinges on selecting clinically relevant targets, utilizing translational models, and generating robust efficacy and safety data. Early engagement with regulatory authorities and incorporation of feedback into study designs also enhance the likelihood of downstream success. Our expertise in sleep disorder pharmacology, regulatory strategy, and advanced preclinical technologies positions our clients for successful IND submissions and clinical trial entry.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2026 Protheragen. All rights reserved.